Acute lymphoblastic leukaemia: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• CD19 122
• CD22 33
• ABL1 10
• KMT2A 8
• CD20 8
• TP53 0
• AKT 0
• BCL-2 3
• PI3K 0
• CD123 5
• JAK 2
• CD38 4
• PD-1 3
• RUNX1 0
• mTOR 0
• NPM1 4
• BCMA 4
• NOTCH1 0
• CXCR4 1
• PTEN 0
• CTNNB1 0
• EGFR 0
• HDAC 0
• IDH 0
• MYC 0
• RAS 0
• STAT3 0
• AMPK 0
• CD30 0
• CD40 0
• CD47 0
• ERK 0
• FGFR 0
• MAPK 0
• MDM2 0
• PD-L1 0
• CD33 1
• FLT3 0
• IL-1 0
• IL-17 0
• IL-6 0
• KRAS 0
• MEK 0
• PPAR 0
• RANKL 0
• RB1 0
• TYK2 0
• ALK 0
• AXL 0
• BRCA1 0
• BRD4 0
• BTK 0
• CDK4/6 0
• CDKN2A 0
• CTLA-4 0
• EZH2 0
• FAK 0
• FTO 0
• GPRC5D 1
• GPX4 0

7 of 7+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · F31

  Overcoming CD4 T Cell Dysfunction in Acute Lymphoblastic Leukemia

  University of Minnesota· Minneapolis, United States· US$38,277 awarded in fiscal year 2026· until Sept 2029

• NIH NCI · R41

  Bivalent CD47 Immunotoxin for Targeted Therapy of T-Cell Acute Lymphoblastic Leukemia

  Rock Immune, Inc.· Denver, United States· US$400,000 awarded in fiscal year 2026· until Aug 2027

• NIH NCI · R34

  Adapting a caregiver-directed mHealth intervention to support positive health behaviors in children treated for Acute Lymphoblastic Leukemia

  University of Minnesota· Minneapolis, United States· US$298,864 awarded in fiscal year 2026· until Aug 2029

• NIH NCI · R01

  Targeting inflammatory RAS-mutated AML leukemia stem cells

  Icahn School of Medicine at Mount Sinai· New York, United States· US$573,098 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · R43

  Validating the reduced immunogenicity of novel human-like asparaginases to de-risk clinical development

  Enzyme By Design, Inc.· Chicago, United States· US$400,000 awarded in fiscal year 2026· until Sept 2027

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  SMART-SMAPs: a new paradigm of cell-free cytotoxic immunotherapy for resistant CLL

  Universita Degli Studi di Siena· Siena, Italy· EU contribution €150,000· until Mar 2028· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-RIA

  TOWARDS THE ELIMINATION OF ACUTE LYMPHOBLASTIC LEUKAEMIA IN CHILDREN THROUGH IDENTIFICATION OF THEIR ENVIRONMENTAL CAUSES (ELI-ALL)

  Centre International de Recherche Sur Le Cancer· Lyon 7eme, France· EU contribution €6,502,240· until Aug 2031· 12 countries

• European Commission (Horizon Europe) · HORIZON-RIA

  THERAPEUTIC ANTIBODIES NEUTRALIZING ALL THE ORTHOPOXVIRUS INFECTIOUS FOR HUMANS, INCLUDING SMALLPOX (THANATOS)

  Commissariat A L Energie Atomique Et Aux Energies Alternatives· Paris, France· EU contribution €13,557,641· until Aug 2031· 6 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Role of RAS mutant subclones in the development of High Hyperdiploid B-ALL (RasWayToALL)

  Vib Vzw· Zwijnaarde - Gent, Belgium· EU contribution €200,400· until Jun 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-CSA

  Science, Innovation, Health, Earth, And Life Technologies for ALL (SCIENCE4ALL)

  Istinye University· Istanbul, Türkiye· EU contribution €350,000· until Jun 2028

10 of 294 running projects, newest first. Listed amounts together: US$164.5m + €62.2m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  Clinical Trial of CD38 Monoclonal Antibody Combined With Chemotherapy for T-Cell Acute Lymphoblastic Leukemia

  NCT07585734· Institute of Hematology & Blood Diseases Hospital, China· Updated 14 May 2026

  “drug-associated adverse reactions”Registry text, quoted unchanged. Source

• Terminated

  XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic Leukemia

  NCT05038644· Ehab L Atallah· Updated 8 May 2025

  “Drug expired May 31, 2024.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 6
• Mendelian Randomization Analysis 4
• CRISPR-Cas Systems 5
• Gene Expression Profiling 27
• Sequence Analysis, RNA 2
• Whole Genome Sequencing 1
• Exome Sequencing 1
• Proteomics 7
• Metabolomics 4
• Flow Cytometry 40
• Immunohistochemistry 6
• Circulating Tumor DNA 1
• Xenograft Model Antitumor Assays 50
• Magnetic Resonance Imaging 14
• Machine Learning 11
• Deep Learning 8
• Cohort Studies 26
• Genome-Wide Association Study 8

• Neurovascular coupling alterations in children with acute lymphoblastic leukemia after chemotherapy: an ASL and rs-fMRI study.

  Brain Res Bull, Aug 2026

• Bilateral optic nerve infiltration and leukaemic retinopathy as initial signs of relapsed B cell acute lymphoblastic leukaemia with CNS and testicular involvement.

  BMJ Case Rep, Jul 2026

• CAA or not? When cerebral microbleeds are not enough.

  Neurol Sci, May 2026

• Central nervous system infection associated with Human herpesvirus 7 presenting with predominant persecutory delusions as initial psychiatric manifestations after allogeneic stem cell transplantation: a rare case report with diagnostic and therapeutic implications.

  BMC Infect Dis, May 2026

• Altered glymphatic-related MRI markers in children with acute lymphoblastic and myeloid leukemia at diagnosis.

  Cancer Imaging, May 2026

• B-Acute Lymphoblastic Leukemia Masquerading as Multifocal Langerhans Cell Histiocytosis: a Diagnostic Paradigm Shift.

  Clin Lab, Apr 2026

• T-cell lymphoblastic lymphoma of the breast: A retrospective observational study and literature review.

  Medicine (Baltimore), Mar 2026

• The Noninvasive Diagnosis of Central Nervous System Leukemia by Specifically Enhanced Magnetic Resonance Imaging.

  Anal Chem, Mar 2026

• Human herpesvirus 6 and non-human herpesvirus 6 limbic encephalitis in children with allogeneic stem cell transplantation: A case series.

  Brain Dev, Feb 2026

• Circumscribed low-grade astrocytoma with a synchronous occipital lesion of uncertain pathology in an adolescent with T-cell lymphoblastic lymphoma.

  BMJ Case Rep, Jan 2026

See which targets of this disease your abstract mentions, and go to the people working on them.